Early detection of lung cancer can decrease lung cancer-related mortality by up to 20 percent1. We are committed to providing diagnostic solutions that support early identification of lung cancer.
With more than 1.6 million nodules detected incidentally each year2, clinical lung cancer risk assessment has become a critical component of managing patients. The Nodify™ testing strategy is designed to help quickly and accurately decipher the of malignancy of a lung nodule from a single blood draw.
We strive to transform lung cancer treatment standards by equipping physicians with the right information at the right time. Biodesix Lung Reflex® testing delivers integrated blood-based genomic and proteomic molecular results within 72 hours, expediting time to treatment compared with tissue-based testing.